| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
THERAPEUTIC REVIEW |
From the Hartford Hospital Drug Information Center, Hartford, Connecticut, and the University of Connecticut School of Pharmacy, Storrs, Connecticut.
Levosimendan is a novel calcium sensitizing agent in development for the treatment of acute and chronic heart failure. The agent increases myocardial force without increasing myocyte calcium concentrations, thus reducing the possibility for myocardial necrosis. In addition, the agent also causes vasodilation of coronary and peripheral vessels to improve coronary blood flow and reduce afterload. The short half-life is a benefit for intravenous administration but could be problematic for the drug's use in chronic heart failure. The risk of the development of arrhythmias from levosimendan appears small secondary to an increase in the QTc interval of 15 msec but needs to be evaluated in light of the ability of levosimendan to open adenosine triphosphate (ATP)-sensitive potassium channels. In addition, the agent has not been studied in patients with additional risks for torsades de pointes. Levosimendan has been shown to have beneficial survival effects in several populations; its use improves patient outcomes relative to the standard of care and has the potential to reduce hospital costs associated with heart failure.
Key Words: Levosimendan • acute decompensated heart failure • pharmacokinetics • calcium sensitization
Address for reprints: C. Michael White, PharmD, Hartford Hospital Drug Information Center, 80 Seymour Street, P.O. Box 5037, Hartford, CT 06102-5037.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Jorgensen, O. Bech-Hanssen, E. Houltz, and S.-E. Ricksten Effects of Levosimendan on Left Ventricular Relaxation and Early Filling at Maintained Preload and Afterload Conditions After Aortic Valve Replacement for Aortic Stenosis Circulation, February 26, 2008; 117(8): 1075 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J T Parissis, S Adamopoulos, D Farmakis, G Filippatos, I Paraskevaidis, F Panou, E Iliodromitis, and D Th Kremastinos Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure Heart, December 1, 2006; 92(12): 1768 - 1772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Garcia-Gonzalez, A. Dominguez-Rodriguez, J. J. Ferrer-Hita, P. Abreu-Gonzalez, and M. B. Munoz Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics Eur J Heart Fail, November 1, 2006; 8(7): 723 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. De Luca, W. S. Colucci, M. S. Nieminen, B. M. Massie, and M. Gheorghiade Evidence-based use of levosimendan in different clinical settings Eur. Heart J., August 2, 2006; 27(16): 1908 - 1920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Raja and B. S. Rayen Levosimendan in Cardiac Surgery: Current Best Available Evidence Ann. Thorac. Surg., April 1, 2006; 81(4): 1536 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L Earl and J. T Fitzpatrick Levosimendan: A Novel Inotropic Agent for Treatment of Acute, Decompensated Heart Failure Ann. Pharmacother., November 1, 2005; 39(11): 1888 - 1896. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
